Technology | December 12, 2014

GE Brings Back Signa MRI Brand With New Line of Systems

GE Healthcare’s new MRI systems launched at RSNA 2014 aim to address clinicians’ pain points

MRI systems, RSNA 2014, Signa Creator, Signa Explorer

Image courtesy of GE Healthcare

December 12, 2014 — GE Healthcare introduced two 510(k) pending 1.5T MRI systems, Signa Creator and Signa Explorer at RSNA 2014. These systems were designed to help clinicians improve workflow, lower cost of ownership and impact patient comfort.

Both Signa Creator and Explorer use 34 percent less power than previous generation MRI systems and require a smaller footprint for installation.

Signa Creator covers a range of productivity-enhancing applications including: “eyes to thighs” coverage, neuro performance with automated motion correction, MSK performance with cartilage mapping, multi-planar body imaging with quantitative capabilities and vascular performance with non-contrast and automated time-resolved imaging. Signa

Creator also helps clinicians save time with an automated workflow, including: volumetric imaging acquisitions like Cube, automated brain exams via Ready Brain and simplified whole body diffusion imaging. OpTix Optical RF technology also can help boost image quality with premium analog to digital signal conversion that can provide a gain in SNR of up to 27 percent over conventional analog signal receivers.

Signa Explorer offers clinicians the same workflow as Signa Creator with an added patient-comfort touch, Silent Scan neuro exam and Mavric SL. Silent Scan, GE Healthcare’s revolutionary quiet technology, takes patient comfort to a new level. Conventional MRI scanners can generate noise in excess of 110 decibels (dBA), the equivalent of a rock concert or jackhammer levels. The Silenz pulse sequence reduces the scan to just three dBA above ambient noise for neuro exams. Mavric SL brings the power of MRI to patients with metal implants by enabling visualization of soft tissue and bone near the implant.

Both systems are pending FDA review and are not cleared for sale.

For more information: www.gehealthcare.com

Related Content

ADHD Medication May Affect Brain Development in Children

Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al.

News | Neuro Imaging | August 16, 2019
A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s...
Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro
Technology | Interventional Radiology | August 16, 2019
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
Synaptive Medical Launches Modus Plan With Automated Tractography Segmentation
Technology | Neuro Imaging | August 07, 2019
Synaptive Medical announced the U.S. launch and availability of Modus Plan featuring BrightMatter AutoSeg. This release...
Canon Medical Introduces Encore Orian MR Upgrade Program
News | Magnetic Resonance Imaging (MRI) | August 06, 2019
Canon Medical Systems USA Inc. is helping to provide low-cost patient care solutions for its customers with the launch...
FDA Issues Draft Guidance on Medical Device Safety in MRI Environment
News | Magnetic Resonance Imaging (MRI) | August 01, 2019 | Jeff Zagoudis, Associate Editor
The U.S. Food and Drug Administration (FDA) issued a new draft guidance titled Testing and Labeling Medical Devices for...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...